Immix Biopharma, Inc. (IMMX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Immix Biopharma, Inc. (IMMX) Healthcare & Pipeline Overview

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation. Their lead candidate, IMX-110, is in Phase 1b/2a trials for soft tissue sarcoma and solid tumors, positioning them in the competitive biotechnology sector with a focus on targeted therapies.

What Is the Investment Thesis for IMMX?

Immix Biopharma presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology companies. The primary value driver is the successful development and commercialization of IMX-110, currently in Phase 1b/2a trials. Positive clinical data could significantly increase the company's valuation. The collaboration with BeiGene Ltd. provides validation and potential future revenue streams. However, the company faces significant regulatory and clinical trial risks. Failure to achieve positive clinical outcomes or secure regulatory approvals could negatively impact the stock. With a market cap of $743M and a beta of 0.21, IMMX offers exposure to the biotechnology sector, but investors should carefully consider the inherent risks associated with early-stage pharmaceutical development.

Based on FMP financials and quantitative analysis

IMMX Key Highlights

IMX-110 is in Phase 1b/2a clinical trials for soft tissue sarcoma and solid tumors, representing a key milestone in the company's drug development pipeline.

• Collaboration with BeiGene Ltd. for a combination Phase 1b clinical trial of IMX-110 and anti-PD-1 Tislelizumab provides external validation and potential for accelerated development.
• IMX-111, a tissue-specific biologic for colorectal cancers, and IMX-120, targeting ulcerative colitis and severe Crohn's disease, diversify the company's therapeutic focus.
• The company's focus on tissue-specific therapeutics aims to improve efficacy and reduce side effects compared to traditional treatments.
• With only 18 employees, Immix Biopharma operates with a lean structure, potentially allowing for efficient resource allocation.

Who Are IMMX's Competitors?

IMMX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMMX's Key Strengths?

Proprietary tissue-specific drug delivery technology.

• Lead candidate IMX-110 in Phase 1b/2a clinical trials.
• Collaboration with BeiGene Ltd.
• Focus on unmet needs in oncology and inflammation.

What Are IMMX's Weaknesses?

Clinical-stage company with no approved products.

• Limited financial resources.
• Small number of employees.
• High reliance on the success of IMX-110.

What Could Drive IMMX Stock Higher?

IMMX catalyst: Interim data readout from the Phase 1b/2a clinical trial of IMX-110 in soft tissue sarcoma and solid tumors (projected for Q4 2026).

• Initiation of Phase 1 clinical trial for IMX-111 in colorectal cancers (expected in Q1 2027).
• Continued enrollment and progress in the Phase 1b clinical trial of IMX-110 in combination with anti-PD-1 Tislelizumab in collaboration with BeiGene Ltd.
• Advancements in preclinical development of IMX-120 for ulcerative colitis and severe Crohn's disease.

What Are the Key Risks for IMMX?

Negative return on equity (-73.2%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive clinical outcomes in ongoing and planned clinical trials.
• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies and other emerging biotech firms.
• Inability to secure additional funding to support ongoing research and development activities.
• Dependence on key personnel and the ability to retain and attract talent.

What Are the Growth Opportunities for IMMX?

• Successful Completion of IMX-110 Clinical Trials: The successful completion of Phase 1b/2a clinical trials for IMX-110 in soft tissue sarcoma and solid tumors represents a significant growth opportunity. Positive data could lead to accelerated regulatory pathways and potential partnerships, expanding the market reach and revenue potential. The market for soft tissue sarcoma treatment is projected to reach $2.8 billion by 2028, indicating a substantial commercial opportunity for Immix Biopharma.
• Expansion of Pipeline with IMX-111 and IMX-120: The development of IMX-111 for colorectal cancers and IMX-120 for ulcerative colitis and Crohn's disease offers diversification and growth potential. These tissue-specific biologics target large patient populations with significant unmet needs. The global market for colorectal cancer therapeutics is expected to reach $17.5 billion by 2027, while the market for inflammatory bowel disease treatments is projected to reach $20.6 billion by 2028.
• Strategic Partnerships and Collaborations: Immix Biopharma can leverage strategic partnerships and collaborations to accelerate drug development and commercialization. The existing collaboration with BeiGene Ltd. demonstrates the potential for such partnerships to enhance research and development efforts. Further collaborations with larger pharmaceutical companies could provide access to funding, expertise, and distribution networks, driving growth and market penetration.
• Expansion into New Therapeutic Areas: Immix Biopharma's expertise in tissue-specific therapeutics can be applied to new therapeutic areas beyond oncology and inflammation. Exploring opportunities in other diseases with targeted drug delivery needs could expand the company's market reach and revenue streams. This diversification strategy could mitigate risks associated with relying on a limited number of drug candidates.
• Acquisition or Licensing of Complementary Technologies: Immix Biopharma could pursue acquisitions or licensing agreements to acquire complementary technologies and expand its intellectual property portfolio. This strategy could enhance its drug development capabilities and create synergies within its existing pipeline. Acquiring technologies that improve drug delivery or target specific tissues could provide a competitive advantage and drive long-term growth.

What Threats Does IMMX Face?

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from established pharmaceutical companies.
• Patent expirations.

What Are IMMX's Competitive Advantages?

• Proprietary tissue-specific drug delivery technology.
• Patent protection for key drug candidates.
• Clinical trial data demonstrating efficacy and safety.
• Strategic collaborations with established pharmaceutical companies.

What Does IMMX Do?

Immix Biopharma, Inc., founded in 2012 and headquartered in Los Angeles, California, is a clinical-stage biopharmaceutical company dedicated to developing innovative tissue-specific therapeutics. The company focuses on addressing unmet needs in oncology and inflammation, leveraging its proprietary technology to create targeted treatments. Immix Biopharma's lead product candidate, IMX-110, is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors. This trial aims to evaluate the safety and efficacy of IMX-110 in patients with advanced cancers. In addition to IMX-110, Immix Biopharma is also developing IMX-111, a tissue-specific biologic designed for the treatment of colorectal cancers, and IMX-120, a tissue-specific biologic targeting ulcerative colitis and severe Crohn's disease. These programs reflect the company's commitment to expanding its pipeline and addressing a range of inflammatory and oncologic indications. Immix Biopharma has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab, enhancing its research and development efforts through strategic partnerships.

What Products and Services Does IMMX Offer?

• Develop tissue-specific therapeutics for oncology.
• Develop tissue-specific therapeutics for inflammation.
• Conduct Phase 1b/2a clinical trials for IMX-110 in soft tissue sarcoma and solid tumors.
• Develop IMX-111, a tissue-specific biologic for colorectal cancers.
• Develop IMX-120, a tissue-specific biologic for ulcerative colitis and severe Crohn's disease.
• Collaborate with BeiGene Ltd. for a combination Phase 1b clinical trial.

How Does IMMX Make Money?

• Develop and patent novel tissue-specific therapeutics.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Commercialize approved therapeutics directly or through partnerships.

What Industry Does IMMX Operate In?

Immix Biopharma operates within the highly competitive biotechnology industry, characterized by rapid innovation and significant regulatory hurdles. The market for oncology and inflammatory disease therapeutics is substantial, driven by an aging population and increasing prevalence of chronic conditions. Companies like Immix Biopharma focus on developing novel therapies to address unmet medical needs. The success of these companies depends on clinical trial outcomes, regulatory approvals, and the ability to secure funding. The industry is also subject to intense competition from established pharmaceutical companies and other emerging biotech firms.

Who Are IMMX's Key Customers?

• Patients with soft tissue sarcoma and solid tumors.
• Patients with colorectal cancers.
• Patients with ulcerative colitis and severe Crohn's disease.
• Healthcare providers who prescribe and administer the company's therapeutics.

How Immix Biopharma, Inc. Is Valued

Immix Biopharma, Inc. carries a market capitalization of $743M, placing it in the small-cap category. Relative to its peer group, IMMX's quantitative score of 63/100 is below the peer average of 89/100.

Company Profile

Immix Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Ilya Rachman. IMMX has traded publicly since 2021.

Return on equity for Immix Biopharma, Inc. stands at -73.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -36.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.3%, the inverse of the P/E and a quick read on earnings relative to price.

Immix Biopharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 42.07 places it in the safe zone, indicating low near-term bankruptcy risk.

Immix Biopharma, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 3.8% below estimates on average.

Wall Street analysts project Immix Biopharma, Inc. revenue of about $12.1M for fiscal 2026, with EPS near $-0.74. The estimate reflects 6 contributing analysts.

IMMX Financials

IMMX Latest News

IMMX Analyst Consensus

IMMX MoonshotScore

What Investors Ask About Immix Biopharma, Inc. (IMMX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources